GSK-106 is a useful negative control for PAD4 inhibitors (GSK-121 and GSK-484). It does not inhibit PAD4 nor does it prevent the citrullination of PAD4 target proteins or the formation of neutrophil extracellular traps in mouse or human neutrophils (IC₅₀s > 100 µM).